Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses
Open Access
- 1 October 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (19) , 9398-9406
- https://doi.org/10.1158/0008-5472.can-07-1063
Abstract
Clinical trials have proven oncolytic virotherapy to be safe but not effective. We have shown that oncolytic viruses (OV) injected into intracranial gliomas established in rodents are rapidly cleared, and this is associated with up-regulation of markers (CD68 and CD163) of cells of monocytic lineage (monocytes/microglia/macrophages). However, it is unclear whether these cells directly impede intratumoral persistence of OV through phagocytosis and whether they infiltrate the tumor from the blood or the brain parenchyma. To investigate this, we depleted phagocytes with clodronate liposomes (CL) in vivo through systemic delivery and ex vivo in brain slice models with gliomas. Interestingly, systemic CL depleted over 80% of peripheral CD163+ macrophages in animal spleen and peripheral blood, thereby decreasing intratumoral infiltration of these cells, but CD68+ cells were unchanged. Intratumoral viral titers increased 5-fold. In contrast, ex vivo CL depleted only CD68+ cells from brain slices, and intratumoral viral titers increased 10-fold. These data indicate that phagocytosis by both peripheral CD163+ and brain-resident CD68+ cells infiltrating tumor directly affects viral clearance from tumor. Thus, improved therapeutic efficacy may require modulation of these innate immune cells. In support of this new therapeutic paradigm, we observed intratumoral up-regulation of CD68+ and CD163+ cells following treatment with OV in a patient with glioblastoma. [Cancer Res 2007;67(19):9398–406]Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- Cell-based Delivery of Oncolytic Viruses: A New Strategic Alliance for a Biological Strike Against CancerMolecular Therapy, 2007
- The status of gene therapy for brain tumorsExpert Opinion on Biological Therapy, 2007
- Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral ImmunityMolecular Therapy, 2007
- Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence ImagingMolecular Therapy, 2006
- Immunoglobulin G Antibody-Mediated Enhancement of Measles Virus Infection Can Bypass the Protective Antiviral Immune ResponseJournal of Virology, 2006
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences, 2006
- CD163 Identifies Perivascular Macrophages in Normal and Viral Encephalitic Brains and Potential Precursors to Perivascular Macrophages in BloodThe American Journal of Pathology, 2006
- The Case for Immunosuppression in Clinical Gene TransferMolecular Therapy, 2005
- An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain TumorCancer Research, 2005
- Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysisGene Therapy, 2004